Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke.

Publisher: Saunders Country of Publication: United States NLM ID: 9111633 Publication Model: Print Cited Medium: Internet ISSN: 1532-8511 (Electronic) Linking ISSN: 10523057 NLM ISO Abbreviation: J Stroke Cerebrovasc Dis Subsets: MEDLINE

Publication: Philadelphia, PA : Saunders
Original Publication: New York, NY : Demos Publications, [1991-

Angiotensin II Type 1 Receptor Blockers/*therapeutic use ; Benzimidazoles/*therapeutic use ; Benzoates/*therapeutic use ; Blood Platelets/*drug effects ; Brain Ischemia/*complications ; Hypertension/*complications ; Losartan/*therapeutic use ; Platelet Aggregation Inhibitors/*therapeutic use ; Stroke/*drug therapy; Aged ; Angiotensin II Type 1 Receptor Blockers/pharmacology ; Benzimidazoles/pharmacology ; Benzoates/pharmacology ; Biomarkers/blood ; Blood Platelets/immunology ; Brain Ischemia/blood ; Brain Ischemia/drug therapy ; Chronic Disease ; Female ; Flow Cytometry ; Humans ; Hypertension/blood ; Hypertension/drug therapy ; Losartan/pharmacology ; Male ; Middle Aged ; P-Selectin/blood ; Platelet Aggregation/drug effects ; Platelet Aggregation Inhibitors/pharmacology ; Platelet Function Tests ; Stroke/blood ; Stroke/etiology ; Telmisartan ; Time Factors ; Treatment Outcome

Antiplatelet effects of angiotensin II receptor blocker have been suggested, but satisfactory results in clinical settings are lacking. We investigated spontaneous platelet aggregation (SPA) and CD62P levels in patients with hypertension and chronic-stage ischemic stroke. The study comprised 35 patients assigned to losartan (50 mg/day) or telmisartan (40 mg/day) for 4 weeks randomly. SPA was evaluated using laser-scattered light aggregometry and CD62P levels using whole blood flow cytometry before and after treatment. SPA was not significantly reduced after losartan or telmisartan treatment. CD62P was significantly reduced after losartan treatment (P = .016), but no significant differences were noted with telmisartan. These findings suggest that standard doses of losartan display antiplatelet effect as measured by CD62P levels.

0 (Angiotensin II Type 1 Receptor Blockers)
0 (Benzimidazoles)
0 (Benzoates)
0 (Biomarkers)
0 (P-Selectin)
0 (Platelet Aggregation Inhibitors)
JMS50MPO89 (Losartan)
U5SYW473RQ (Telmisartan)

Date Created: 20070912 Date Completed: 20070928 Latest Revision: 20220331

20231215

10.1016/j.jstrokecerebrovasdis.2007.07.003

17845921